US07160F4046 - Common Stock
It's time for a dive into the biggest pre-market stock movers as we check out all of the latest news traders need to know about on Friday!
Although Baudax Bio saw significant interest because of its orphan drug designation, BXRX stock must climb a wall of worry.
BXRX Baudax Bio files to sell 15M shares of common stock for holders. This prospectus relates to the offering and resale by Alumni Capital LP. This preliminary prospectus is not an offer...
MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on...
MALVERN, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (Nasdaq: BXRX), a biotechnology company focused on...
Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg Asset for Hemophilia A Continuing to...
We're starting off the day with a breakdown of all the biggest pre-market stock movers traders need to know about on Friday!
Baudax Bio (BXRX) said on Friday that it had acquired TeraImmune, a Treg research companyBXRX shares more than double, up +163.4%. Under the deal, TeraImmune's outstanding equity...
TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax ...